InnovHeart Secures €4M to Propel Next-Generation Mitral Valve Therapy with the Saturn Prosthesis

InnovHeart S.r.l. is thrilled to announce a significant milestone in our journey toward revolutionizing the treatment of mitral valve disease. Our company, with strategic locations in Milan, Italy and Boston, Massachusetts, has successfully raised €4,000,000 in its latest funding round. This pivotal investment underscores the confidence our investors have in our mission to develop innovative, minimally invasive solutions for patients in need. At the heart of our developments is the novel TMVR Saturn Prosthesis—an advanced, low-profile transcatheter device meticulously engineered to match the complex anatomy of the mitral valve. With design features that allow for both Trans-apical and Trans-septal delivery, the Saturn Prosthesis promises a versatile and patient-friendly therapeutic option, potentially transforming the standard of care in this critical field. The newly secured funding will accelerate our clinical trials, currently underway to validate the performance, safety, and effectiveness of the Saturn Prosthesis. These trials are a critical step toward obtaining regulatory approval, ensuring that our device meets the highest quality and reliability standards. The investment will not only bolster our research and development initiatives but also expand our clinical research infrastructure and enhance our global outreach efforts. By solidifying our financial foundation, InnovHeart is well-positioned to push forward the boundaries of medical technology and address an urgent unmet need in cardiology. Our unwavering commitment is to bring patients a safe, effective, and easy-to-use transcatheter technology that ultimately replaces incompetent mitral valves, improving quality of life and clinical outcomes in populations worldwide.